Here's the executive who will be responsible for manufacturing the HeartSaver. Based on his credentials he looks to be very credible...
WORLDHEART APPOINTS VICE PRESIDENT, MANUFACTURING
OTTAWA, Ontario, Canada, Nov. 19 /CNW/ - Dr. Tofy Mussivand, President of World Heart Corporation (WorldHeart) today announced the appointment of Mr. Robert W. Corson as Vice President, Manufacturing.
The appointment reflects the move to production by WorldHeart of its HEARTSAVERvad(TM), related remote energy transfer and remote patient monitoring products.
'Mr. Corson brings to WorldHeart a proven record of leadership in
manufacturing of highly technical products. Mr. Corson has some 25 years experience in electronics and microelectronics manufacturing in Canada, including 15 years with NORTEL. His experience also includes 7 years as President and CEO of International Epitek Inc. Most recently as President and CEO of CompAS Electronics Inc., Mr. Corson led the company to establish a strong, profitable business as contract manufacturers with revenues of more than $55 million in 1997. Of particular significance to WorldHeart, was Mr. Corson's role in certification of two manufacturing plants to ISO 9002 and a third plant to ISO 9001 standards. Production of devices for a US-based
medical device manufacturing company is a significant part of the output of these facilities. His depth of experience in this specialized area of manufacturing and his success as CEO of a successful public company gives Mr. Corson an excellent base from which to lead WorldHeart in immediate initial production and expected rapid development of advanced manufacturing capability,'' Dr. Mussivand said.
''WorldHeart has a unique opportunity with its HEARTSAVERvad(TM) and
related products,'' Mr. Corson said. ''I see here an opportunity to play a role in creating a major medical devices enterprise.''
WorldHeart is a medical devices business focused on commercialization of artificial heart and related technologies under development at the
Cardiovascular Devices Division of the Ottawa Heart Institute Research
Corporation, a not-for-profit research affiliate of the University of Ottawa Heart Institute. WorldHeart is a public company whose stock trades on the NASDAQ SmallCap Market (ticker symbol: WHRTF) and the Canadian Dealing Network (ticker symbol: WHRT).
Any forward-looking statements in this release are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation, risks in product development and market acceptance of and demand for the company's products, risks of downturns in economic conditions generally, and in the medical devices markets, risks associated with costs and delays posed by government regulation, limitations on third party reimbursement, inability to protect
proprietary technology, potential product liability and other risks detailed in the company's filings with the U.S. Securities and Exchange Commission.
All financial figures are prepared in accordance with Canadian Generally Accepted Accounting Principles (GAAP) and are expressed in Canadian dollars.
-30-
For further information: Sandy Armstrong, Public Relations Officer, World Heart
Corporation, Tel.: (613) 226-4278, Fax: (613) 226-4744, E-Mail:
mwyndham-west@worldheart.com |
